Do omega-3 fish oil supplements protect the heart?

Numbers match the citations in the article. A working link isn't proof that a page supports a claim; check the quoted passage and date.

1. 1

   Formulation-Specific Cardiovascular Outcomes with High-Dose Eicosapentaenoic Acid: A Systematic Review and Meta-analysis.

   American journal of cardiovascular drugs : drugs, devices, and other interventions (Faheem et al.)Published May 2, 2026Checked Oct 4, 2026

   “Overall effects on recurrent myocardial infarction and revascularization were not statistically significant, but both became significant after exclusion of STRENGTH, the only mixed EPA/DHA cardiovascular outcomes trial. No significant effect was observed for ischemic stroke, cardiovascular death, or high-sensitivity C-reactive protein (hs-CRP). CHERRY and EVAPORATE both suggested attenuation of plaque progression, but these imaging studies were not pooled because intravascular ultrasound and coronary computed tomography angiography-derived measures were not directly comparable.ConclusionHigh-dose EPA-dominant therapy was associated with fewer unstable angina hospitalizations, and formulation appeared to modify clinical benefit. Among blinded, placebo-controlled, cardiovascular outcomes trials, 4 g/day icosapent ethyl is the only formulation independently associated with reduced cardiovascular events. Larger formulation-specific trials are needed to clarify the roles of purified EPA, mixed EPA/DHA regimens, and patient selection.RegistrationPROSPERO identifier number: CRD420251063069.”

2. 2

   Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability.

   Nutrients (Egalini et al.)Published Aug 4, 2026Checked Oct 4, 2026

   “While traditional low-dose mixed formulations often failed to show significant benefits, high-dose purified EPA (icosapent ethyl, 4 g/day) has demonstrated a substantial reduction in residual cardiovascular risk in specific populations. However, this clinical success is accompanied by a modest but consistent increase in atrial fibrillation risk at pharmacological doses, suggesting a need for better risk stratification. We highlight that therapeutic efficacy is closely tied to bioavailability-driven by chemical form and dietary context. In this setting, objective metrics such as the ω-3 Index or EPA/arachidonic acid (AA) ratio are discussed as validated biomarkers of ω-3 status that, although not yet incorporated into clinical guidelines as routine treatment targets, may help account for inter-individual variability. Furthermore, we address the environmental burden of marine-derived oils, considering microalgae-based alternatives as sustainable solutions. Ultimately, this review advocates for a more nuanced approach that integrates clinical evidence, the potential of biomarker monitoring, and global environmental responsibility.”

3. 3

   Diet and Risk of Cardiovascular Disease.

   The American journal of medicine (Sultan et al.)Published Oct 1, 2026Checked Oct 4, 2026

   “Moderate egg intake is acceptable within a high-quality dietary pattern; preparation method meaningfully modifies risk. Habitual moderate coffee consumption is neutral to modestly cardioprotective; unfiltered preparations elevate low-density lipoprotein cholesterol (LDL-C) through diterpene retention. No safe cardiovascular benefit threshold for alcohol can be established; binge drinking is consistently harmful. Low-carbohydrate and ketogenic diets improve select metabolic parameters but raise concern for sustained LDL-C and apolipoprotein B elevation, particularly with animal-derived macronutrient substitution. Omega-3 supplementation reduces coronary heart disease and myocardial infarction risk dose-dependently; atrial fibrillation risk is confined to high-dose formulations in high-risk populations. The Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diets carry the most robust evidence for cardiovascular risk reduction; the Portfolio diet provides effective non-pharmacologic lipid lowering. Overall dietary pattern quality predicts cardiovascular risk more reliably than any single food or nutrient.”

4. 4

   Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials including 114 592 Individuals.

   Circulation. Arrhythmia and electrophysiology (Abuknesha et al.)Published Jul 28, 2026Checked Oct 4, 2026

   “Only studies including patients at high-risk for cardiovascular disease who were treated with high-doses of EPA/DHA (>1500 mg/d) showed a statistically significant increase in AF risk with a pooled odds ratio (OR) of 1.43 (95% CI, 1.14-1.79) and an absolute risk difference of 0.8% (0.40%-1.1%). None of the other 3 groups showed statistically significant levels of AF risk (odds ratios, 1.07 [high risk-low dose], 1.06 [low risk-low dose], and 1.03 [low risk-high dose]).ConclusionsThis meta-analysis suggests that high-dose EPA/DHA treatment is associated with an increased risk of AF in patients at high cardiovascular disease risk, whereas low-dose EPA/DHA does not appear to increase AF risk, even in high-risk populations. Further prospective studies are needed to evaluate any potential increased risk of higher doses balanced against potential benefits.”

5. 5

   Circulating Omega-3 Fatty Acids and Cardiometabolic Outcomes: A Systematic Review of Publications From UK Biobank.

   Lipids (Firdous & Calder)Published Jul 29, 2026Checked Oct 4, 2026

   “Three databases (EMBASE, MEDLINE, CINAHL) were searched in September 2025 using key words. Based on inclusion/exclusion criteria, 16 publications were selected for inclusion (two cross-sectional and 14 longitudinal with a follow-up of 11 to 14 years). Sample size varied between 20,338 and 273,834 across the included studies. Eleven studies reported on CVD outcomes and five on metabolic outcomes. Plasma total omega-3 fatty acids and DHA were inversely associated with risk of coronary heart disease, CVD mortality, heart failure, haemorrhagic stroke and severe fatty liver disease. Plasma total omega-3 fatty acids were also inversely associated with risk of prediabetes and type-2 diabetes, while plasma DHA was also inversely associated with risk of coronary heart disease mortality, ischemic stroke and fatty liver disease. It is concluded that publications based on UK Biobank consistently demonstrate a significant association between higher levels of total omega-3 fatty acids or DHA in plasma and lower likelihood of poor cardiometabolic health outcomes, providing support for guidance for the population to achieve recommended intakes of these fatty acids.”

6. 6

   Omega−3 fatty acid (Wikipedia)

   WikipediaPublished Sep 29, 2026Checked Oct 4, 2026

   “Omega−3 fatty acids, also called omega−3 oils, ω−3 fatty acids or n−3 fatty acids, are polyunsaturated fatty acids (PUFAs) characterized by the presence of a double bond three atoms away from the terminal methyl group (numbered ω, the last letter of the Greek alphabet) in their chemical structure. They are widely distributed in nature, are important constituents of animal lipid metabolism, and play an important role in the human diet and in human physiology. The three types of omega−3 fatty acids involved in human physiology are α-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). ALA is found in some land plants, while DHA and EPA are found in algae and fish. Marine algae and phytoplankton are primary sources of omega−3 fatty acids. DHA and EPA accumulate in fish that eat these algae. Common sources of land plants containing ALA include walnuts, chia seeds, and flaxseeds as well as hempseed oil, while sources of EPA and DHA include fish and fish oils, and algae oil. Almost without exception, animals are unable to synthesize the essential omega−3 fatty acid ALA and can only obtain it through diet.”